Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 12/2006

01-12-2006 | Original Article

CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells

Authors: Andrew Lodge, Ping Yu, Michael B. Nicholl, Ian E. Brown, Carl-Christian A. Jackson, Karin Schreiber, Sonia L. Sugg, Hans Schreiber, Joel Shilyansky

Published in: Cancer Immunology, Immunotherapy | Issue 12/2006

Login to get access

Abstract

Absence of CD4+ T cell help has been suggested as a mechanism for failed anti-tumor cytotoxic T lymphocytes (CTL) response. We examined the requirement for CD4+ T cells to eliminate an immunogenic murine fibrosarcoma (6132A) inoculated into the peritoneal cavity. Immunocompetent C3H mice eliminated both single and repeat intraperitoneal (IP) inoculums, and developed high frequency of 6132A-specific interferon-γ (IFNγ)-producing CTL in the peritoneal cavity. Adoptive transfer of peritoneal exudate cells (PEC) isolated from control mice, protected SCID mice from challenge with 6132A. In contrast, CD4 depleted mice had diminished ability to eliminate tumor and succumbed to repeat IP challenges. Mice depleted of CD4+ T cells lacked tumor-specific IFNγ producing CTL in the peritoneal cavity. Adoptive transfer of PEC from CD4 depleted mice failed to protect SCID mice from 6132A. However, splenocytes isolated from same CD4 depleted mice prevented tumor growth in SCID mice, suggesting that 6132A-specific CTL response was generated, but was not sustained in the peritoneum. Treating CD4 depleted mice with agonist anti-CD40 antibody, starting on days 3 or 8 after initiating tumor challenge, led to persistence of 6132A-specific IFNγ producing CTL in the peritoneum, and eliminated 6132A tumor. The findings suggest that CTL can be activated in the absence of CD4+ T cells, but CD4+ T cells are required for a persistent CTL response at the tumor site. Exogenous stimulation through CD40 can restore tumor-specific CTL activity to the peritoneum and promote tumor clearance in the absence of CD4+ T cells.
Literature
1.
go back to reference Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM (1997) Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(−/−) mice. J Immunol 159:4665–4675PubMed Manning TC, Rund LA, Gruber MM, Fallarino F, Gajewski TF, Kranz DM (1997) Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(−/−) mice. J Immunol 159:4665–4675PubMed
2.
go back to reference Zhan Y, Corbett AJ, Brady JL, Sutherland RM, Lew AM (2000) CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J Immunol 165:3612–3619PubMed Zhan Y, Corbett AJ, Brady JL, Sutherland RM, Lew AM (2000) CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation. J Immunol 165:3612–3619PubMed
3.
go back to reference Melief CJ (1992) Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58:143–175PubMedCrossRef Melief CJ (1992) Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58:143–175PubMedCrossRef
4.
go back to reference Awwad M, North RJ (1988) Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J Exp Med 168:2193–206CrossRefPubMed Awwad M, North RJ (1988) Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J Exp Med 168:2193–206CrossRefPubMed
5.
go back to reference North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90–95PubMed North RJ, Awwad M (1990) Elimination of cycling CD4+ suppressor T cells with an anti-mitotic drug releases non-cycling CD8+ T cells to cause regression of an advanced lymphoma. Immunology 71:90–95PubMed
6.
go back to reference Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA (2005) The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174:2563–2572PubMed Lyman MA, Nugent CT, Marquardt KL, Biggs JA, Pamer EG, Sherman LA (2005) The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174:2563–2572PubMed
7.
go back to reference Hu HM, Winter H, Urba WJ, Fox BA (2000) Divergent roles for CD4(±) T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 165:4246–4253PubMed Hu HM, Winter H, Urba WJ, Fox BA (2000) Divergent roles for CD4(±) T cells in the priming and effector/memory phases of adoptive immunotherapy. J Immunol 165:4246–4253PubMed
8.
go back to reference Yu Q, Gu JX, Kovacs C, Freedman J, Thomas EK, Ostrowski MA (2003) Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 170:1797–805PubMed Yu Q, Gu JX, Kovacs C, Freedman J, Thomas EK, Ostrowski MA (2003) Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 170:1797–805PubMed
9.
go back to reference Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B (2000) Tumor-specific CD4(+) T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 165:6047–6055PubMed Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B (2000) Tumor-specific CD4(+) T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol 165:6047–6055PubMed
10.
go back to reference Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474–478CrossRefPubMed Ridge JP, Di Rosa F, Matzinger P (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393:474–478CrossRefPubMed
11.
go back to reference Schoenberger (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480–483CrossRefPubMed Schoenberger (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480–483CrossRefPubMed
12.
go back to reference Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478–480CrossRefPubMed Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478–480CrossRefPubMed
13.
go back to reference Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337–339CrossRefPubMed Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337–339CrossRefPubMed
15.
go back to reference Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P (2000) Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 165:2651–2656PubMed Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P (2000) Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 165:2651–2656PubMed
16.
go back to reference Lee BO, Hartson L, Randall TD (2003) CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J Exp Med 198:1759–1764CrossRefPubMed Lee BO, Hartson L, Randall TD (2003) CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment. J Exp Med 198:1759–1764CrossRefPubMed
17.
go back to reference Wang JC, Livingstone AM (2003) Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 171:6339–6343PubMed Wang JC, Livingstone AM (2003) Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo. J Immunol 171:6339–6343PubMed
18.
go back to reference Giuntoli RL II, Lu J, Kobayashi H, Kennedy R, Celis E (2002) Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 8:922–931PubMed Giuntoli RL II, Lu J, Kobayashi H, Kennedy R, Celis E (2002) Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 8:922–931PubMed
19.
go back to reference Sun JC, Bevan MJ (2004) Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J Immunol 172:3385–3389PubMed Sun JC, Bevan MJ (2004) Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J Immunol 172:3385–3389PubMed
20.
go back to reference Sun JC, Williams MA, Bevan MJ (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5:927–933CrossRefPubMed Sun JC, Williams MA, Bevan MJ (2004) CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5:927–933CrossRefPubMed
21.
go back to reference Bourgeois C, Rocha B, Tanchot C (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297:2060–2063CrossRefPubMed Bourgeois C, Rocha B, Tanchot C (2002) A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science 297:2060–2063CrossRefPubMed
22.
go back to reference Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R (1998) Viral immune evasion due to persistence of activated T cells without effector function (see comments). J Exp Med 188:2205–2213CrossRefPubMed Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R (1998) Viral immune evasion due to persistence of activated T cells without effector function (see comments). J Exp Med 188:2205–2213CrossRefPubMed
23.
go back to reference Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW (2004) Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 173:5923–5928PubMed Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW (2004) Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 173:5923–5928PubMed
24.
go back to reference Radoja S, Rao TD, Hillman D, Frey AB (2000) Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J Immunol 164:2619–2628PubMed Radoja S, Rao TD, Hillman D, Frey AB (2000) Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo. J Immunol 164:2619–2628PubMed
25.
go back to reference Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL (2000) Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 6:1351–1364PubMed Saito T, Dworacki G, Gooding W, Lotze MT, Whiteside TL (2000) Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 6:1351–1364PubMed
26.
go back to reference Korb LC, Mirshahidi S, Ramyar K, Sadighi Akha AA, Sadegh-Nasseri S (1999) Induction of T cell anergy by low numbers of agonist ligands. J Immunol 162:6401–6409PubMed Korb LC, Mirshahidi S, Ramyar K, Sadighi Akha AA, Sadegh-Nasseri S (1999) Induction of T cell anergy by low numbers of agonist ligands. J Immunol 162:6401–6409PubMed
27.
go back to reference Tham EL, Shrikant P, Mescher MF (2002) Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J Immunol 168:1190–1197PubMed Tham EL, Shrikant P, Mescher MF (2002) Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response. J Immunol 168:1190–1197PubMed
28.
go back to reference Shrikant P, Mescher MF (1999) Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol 162:2858–2866PubMed Shrikant P, Mescher MF (1999) Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J Immunol 162:2858–2866PubMed
29.
go back to reference McKee MD, Roszkowski JJ, Nishimura MI (2005) T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 3:35CrossRefPubMed McKee MD, Roszkowski JJ, Nishimura MI (2005) T cell avidity and tumor recognition: implications and therapeutic strategies. J Transl Med 3:35CrossRefPubMed
30.
go back to reference Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162:2227–2234PubMed Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162:2227–2234PubMed
31.
go back to reference Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036CrossRefPubMed Pasare C, Medzhitov R (2003) Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299:1033–1036CrossRefPubMed
32.
go back to reference Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT (2004) Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5:1143–1148CrossRefPubMed Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT (2004) Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5:1143–1148CrossRefPubMed
33.
go back to reference Ward PL, Koeppen HK, Hurteau T, Schreiber D (1989) Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 170:217–232CrossRefPubMed Ward PL, Koeppen HK, Hurteau T, Schreiber D (1989) Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J Exp Med 170:217–232CrossRefPubMed
34.
go back to reference Ward LP, Koeppen H, Hurteau T, Rowley DA, Schreiber H (1990) Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent survaillance. Cancer Res 50:3851–3858PubMed Ward LP, Koeppen H, Hurteau T, Rowley DA, Schreiber H (1990) Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent survaillance. Cancer Res 50:3851–3858PubMed
35.
go back to reference Seung LP, Seung SK, Schreiber H (1995) Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res 55:5094–5100PubMed Seung LP, Seung SK, Schreiber H (1995) Antigenic cancer cells that escape immune destruction are stimulated by host cells. Cancer Res 55:5094–5100PubMed
36.
go back to reference Monach P, Meredith SC, Siegel CT, Schreiber H (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2:45–49CrossRefPubMed Monach P, Meredith SC, Siegel CT, Schreiber H (1995) A unique tumor antigen produced by a single amino acid substitution. Immunity 2:45–49CrossRefPubMed
37.
go back to reference Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96:8633–8638CrossRefPubMed Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H (1999) CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96:8633–8638CrossRefPubMed
38.
go back to reference Kedl RM, Mescher MF (1998) Qualitative differences between naive and memory T cells make a major contribution to the more rapid and efficient memory CD8+ T cell response. J Immunol 161:674–683PubMed Kedl RM, Mescher MF (1998) Qualitative differences between naive and memory T cells make a major contribution to the more rapid and efficient memory CD8+ T cell response. J Immunol 161:674–683PubMed
39.
go back to reference Maas RA, Becker MJ, Weimar IS, De Nooy JC, Dullens HF, Den Otter WD (1993) Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice. Immunobiology 188:281–292PubMed Maas RA, Becker MJ, Weimar IS, De Nooy JC, Dullens HF, Den Otter WD (1993) Transfer of tumor immunity by both CD4+ and CD8+ tumor infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumor bearing mice. Immunobiology 188:281–292PubMed
40.
go back to reference Shrikant P, Khoruts A, Mescher MF (1999) CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11:483–493CrossRefPubMed Shrikant P, Khoruts A, Mescher MF (1999) CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11:483–493CrossRefPubMed
41.
go back to reference Noh SH, Yoo CH, Chung HC, Roh JK, Shin DW, Min JS (2001) Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. Oncology 60:24–30CrossRefPubMed Noh SH, Yoo CH, Chung HC, Roh JK, Shin DW, Min JS (2001) Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer. Oncology 60:24–30CrossRefPubMed
42.
go back to reference Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, Lise M (2001) Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 27:125–134 CrossRefPubMed Pilati P, Rossi CR, Mocellin S, Foletto M, Scagnet B, Pasetto L, Lise M (2001) Multimodal treatment of peritoneal carcinomatosis and sarcomatosis. Eur J Surg Oncol 27:125–134 CrossRefPubMed
43.
go back to reference Zinkernagel RM, Leist T, Hengartner H, Althage A (1985) Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J Exp Med 162:2125–2141CrossRefPubMed Zinkernagel RM, Leist T, Hengartner H, Althage A (1985) Susceptibility to lymphocytic choriomeningitis virus isolates correlates directly with early and high cytotoxic T cell activity, as well as with footpad swelling reaction, and all three are regulated by H-2D. J Exp Med 162:2125–2141CrossRefPubMed
44.
go back to reference Bryant J, Day R, Whiteside TL, Herberman RB (1992) Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146:91–103CrossRefPubMed Bryant J, Day R, Whiteside TL, Herberman RB (1992) Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Methods 146:91–103CrossRefPubMed
45.
go back to reference Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A (1983) A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65:109–121CrossRefPubMed Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A (1983) A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 65:109–121CrossRefPubMed
46.
go back to reference Nicholl M, Lodge A, Brown I, Sugg SL, Shilyansky J (2004) Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells (discussion 941–946). J Pediatr Surg 39:941–946CrossRefPubMed Nicholl M, Lodge A, Brown I, Sugg SL, Shilyansky J (2004) Restored immune response to an MHC-II-Restricted antigen in tumor-bearing hosts after elimination of regulatory T cells (discussion 941–946). J Pediatr Surg 39:941–946CrossRefPubMed
47.
go back to reference Tham EL, Mescher MF (2002) The poststimulation program of CD4 versus CD8 T cells (death versus activation-induced nonresponsiveness). J Immunol 169:1822–1828PubMed Tham EL, Mescher MF (2002) The poststimulation program of CD4 versus CD8 T cells (death versus activation-induced nonresponsiveness). J Immunol 169:1822–1828PubMed
48.
go back to reference Deeths MJ, Kedl RM, Mescher MF (1999) CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 163:102–110PubMed Deeths MJ, Kedl RM, Mescher MF (1999) CD8+ T cells become nonresponsive (anergic) following activation in the presence of costimulation. J Immunol 163:102–110PubMed
50.
go back to reference Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601PubMed Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP (2005) CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174:2591–2601PubMed
51.
go back to reference Hornung F, Zheng L, Lenardo MJ (1997) Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol 159:3816–3822PubMed Hornung F, Zheng L, Lenardo MJ (1997) Maintenance of clonotype specificity in CD95/Apo-1/Fas-mediated apoptosis of mature T lymphocytes. J Immunol 159:3816–3822PubMed
52.
go back to reference Sobek V, Balkow S, Korner H, Simon MM (2002) Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes. Eur J Immunol 32:2490–2499CrossRefPubMed Sobek V, Balkow S, Korner H, Simon MM (2002) Antigen-induced cell death of T effector cells in vitro proceeds via the Fas pathway, requires endogenous interferon-gamma and is independent of perforin and granzymes. Eur J Immunol 32:2490–2499CrossRefPubMed
53.
go back to reference Gorak-Stolinska P, Truman JP, Kemeny DM, Noble A (2001) Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha. J Leukoc Biol 70:756–766PubMed Gorak-Stolinska P, Truman JP, Kemeny DM, Noble A (2001) Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha. J Leukoc Biol 70:756–766PubMed
54.
go back to reference Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188:2205–2213CrossRefPubMed Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, Ahmed R (1998) Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med 188:2205–2213CrossRefPubMed
55.
go back to reference Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM (1994) Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 68:4700–4704PubMed Battegay M, Moskophidis D, Rahemtulla A, Hengartner H, Mak TW, Zinkernagel RM (1994) Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J Virol 68:4700–4704PubMed
56.
go back to reference Stevenson PG, Belz GT, Altman JD, Doherty PC (1998) Virus-specific CD8(+) T cell numbers are maintained during gamma- herpesvirus reactivation in CD4-deficient mice. Proc Natl Acad Sci USA 95:15565–15570CrossRefPubMed Stevenson PG, Belz GT, Altman JD, Doherty PC (1998) Virus-specific CD8(+) T cell numbers are maintained during gamma- herpesvirus reactivation in CD4-deficient mice. Proc Natl Acad Sci USA 95:15565–15570CrossRefPubMed
57.
go back to reference Hanson HL, Kang SS, Norian LA, Matsui K, O’Mara LA, Allen PM (2004) CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol 172:4215–4224PubMed Hanson HL, Kang SS, Norian LA, Matsui K, O’Mara LA, Allen PM (2004) CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors. J Immunol 172:4215–4224PubMed
58.
go back to reference Marzo AL, Lake RA, Robinson BW, Scott B (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59:1071–1079PubMed Marzo AL, Lake RA, Robinson BW, Scott B (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59:1071–1079PubMed
59.
go back to reference Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P (2003) Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol 171:6396–6405PubMed Bronte V, Cingarlini S, Apolloni E, Serafini P, Marigo I, De Santo C, Macino B, Marin O, Zanovello P (2003) Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol 171:6396–6405PubMed
60.
go back to reference Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH (2003) Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 170:2727–2733 PubMed Murphy WJ, Welniak L, Back T, Hixon J, Subleski J, Seki N, Wigginton JM, Wilson SE, Blazar BR, Malyguine AM, Sayers TJ, Wiltrout RH (2003) Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol 170:2727–2733 PubMed
61.
go back to reference Bergstrom RT, Silverman DA, Chambers K, Kim JA (2004) CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells. Otolaryngol Head Neck Surg 130:94–103CrossRefPubMed Bergstrom RT, Silverman DA, Chambers K, Kim JA (2004) CD40 monoclonal antibody activation of antigen-presenting cells improves therapeutic efficacy of tumor-specific T cells. Otolaryngol Head Neck Surg 130:94–103CrossRefPubMed
62.
go back to reference van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE (2002) CD40 stimulation leads to effective therapy of CD40(−) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 99:5561–5566CrossRefPubMed van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, Melief CJ, Toes RE (2002) CD40 stimulation leads to effective therapy of CD40(−) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci USA 99:5561–5566CrossRefPubMed
63.
go back to reference Lebre MC, Burwell T, Vieira PL, Lora J, Coyle AJ, Kapsenberg ML, Clausen BE, De Jong EC (2005) Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol 83:525–535CrossRefPubMed Lebre MC, Burwell T, Vieira PL, Lora J, Coyle AJ, Kapsenberg ML, Clausen BE, De Jong EC (2005) Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol 83:525–535CrossRefPubMed
64.
go back to reference Walker TM, Yurochko AD, Burger CJ, Elgert KD (1993) Ia-macrophages and cytokine networks contribute to tumor-induced suppression of CD4+ autoreactive T cells. Immunol Invest 22:169–187PubMedCrossRef Walker TM, Yurochko AD, Burger CJ, Elgert KD (1993) Ia-macrophages and cytokine networks contribute to tumor-induced suppression of CD4+ autoreactive T cells. Immunol Invest 22:169–187PubMedCrossRef
65.
go back to reference Nagata T, Zou JP, Yamamoto N, Ono S, Fujiwara H, Hamaoka T (1993) Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden. Jpn J Cancer Res 84:1181–1189PubMed Nagata T, Zou JP, Yamamoto N, Ono S, Fujiwara H, Hamaoka T (1993) Suppression of anti-tumor CD4+ T cell responsiveness in the tumor-bearing state and its recovery in in vitro culture free of tumor burden. Jpn J Cancer Res 84:1181–1189PubMed
66.
go back to reference Boon T (1993) Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 54:177–180PubMedCrossRef Boon T (1993) Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 54:177–180PubMedCrossRef
Metadata
Title
CD40 ligation restores cytolytic T lymphocyte response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells
Authors
Andrew Lodge
Ping Yu
Michael B. Nicholl
Ian E. Brown
Carl-Christian A. Jackson
Karin Schreiber
Sonia L. Sugg
Hans Schreiber
Joel Shilyansky
Publication date
01-12-2006
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 12/2006
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0147-5

Other articles of this Issue 12/2006

Cancer Immunology, Immunotherapy 12/2006 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine